Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 46
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
Ann Intern Med ; 177(2): 238-245, 2024 02.
Article in English | MEDLINE | ID: mdl-38346308

ABSTRACT

Stroke is a major cause of morbidity, mortality, and disability. The American Heart Association/American Stroke Association recently published updated guidelines on secondary stroke prevention. In these rounds, 2 vascular neurologists use the case of Mr. S, a 75-year-old man with a history of 2 strokes, to discuss and debate questions in the guideline concerning intensity of atrial fibrillation monitoring in embolic stroke of undetermined source, diagnosis and management of moderate symptomatic carotid stenosis, and therapeutic strategies for recurrent embolic stroke of undetermined source in the setting of guideline-concordant therapy.


Subject(s)
Embolic Stroke , Stroke , Teaching Rounds , Male , Humans , Aged , Stroke/etiology , Stroke/prevention & control
2.
Ann Intern Med ; 176(2): 253-259, 2023 02.
Article in English | MEDLINE | ID: mdl-36780653

ABSTRACT

Sepsis is a potentially life-threatening systemic dysregulatory response to infection, and septic shock occurs when sepsis leads to systemic vasodilation and subsequent tissue hypoperfusion. The Surviving Sepsis Campaign published updated guidelines in 2021 on the management of sepsis and septic shock. Here, in the context of a patient with septic shock, 2 critical care specialists discuss and debate conditional guideline recommendations on using lactate to guide resuscitation, the use of balanced crystalloids versus normal saline, and the use of corticosteroids.


Subject(s)
Sepsis , Shock, Septic , Teaching Rounds , Humans , Critical Care , Lactic Acid , Shock, Septic/complications , Shock, Septic/therapy
3.
Ann Intern Med ; 176(12): 1656-1665, 2023 12.
Article in English | MEDLINE | ID: mdl-38079640

ABSTRACT

The proportion of patients with new-onset heart failure who have preserved rather than reduced left ventricular ejection fraction (HFpEF and HFrEF) has been increasing over recent decades. In fact, HFpEF now outweighs HFrEF as the predominant heart failure subtype and likely remains underdiagnosed in the community. This is due in part to an aging population and a rise in other risk factors for HFpEF, including obesity and associated cardiometabolic disease. Whereas the diagnosis of HFrEF is relatively straightforward, the diagnosis of HFpEF is often more challenging because there can be other causes for symptoms, including dyspnea and fatigue, and cardinal physical examination findings of elevated jugular venous pressure or pulmonary congestion may not be evident at rest. In 2022, the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America published a comprehensive guideline on heart failure that included recommendations for the management of HFpEF. The use of diuretics for the management of congestion remained the only class 1 (strong) recommendation. New recommendations included broader use of sodium-glucose cotransporter-2 inhibitors (SGLT2i, class 2a), and angiotensin receptor-neprilysin inhibitors (class 2b). In 2023, the American College of Cardiology published an expert consensus decision pathway for the management of HFpEF that suggests treatment strategies based on sex assigned at birth, ejection fraction, clinical evidence of congestion, and candidacy for SGLT2i therapy. Here, 2 experts, a cardiologist and a geriatrician, discuss their approach to the diagnosis and management of HFpEF and how they would apply guidelines to an individual patient.


Subject(s)
Heart Failure , Sodium-Glucose Transporter 2 Inhibitors , Teaching Rounds , Infant, Newborn , Humans , Aged , Heart Failure/diagnosis , Heart Failure/drug therapy , Stroke Volume , Ventricular Function, Left , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
4.
Ann Intern Med ; 175(2): 267-275, 2022 02.
Article in English | MEDLINE | ID: mdl-35130045

ABSTRACT

Successful screening programs based on cervical cytology have dramatically reduced the incidence of cervical cancer in the United States. Human papillomavirus immunization is poised to reduce it further as an increasing percentage of vaccinated women reach adulthood. A recent guideline from the American Cancer Society advises that cervical cancer screening begin at age 25 and that high-risk human papillomavirus testing is the preferred screening test. The U.S. Preventive Services Task Force recommends screening begin at age 21 and that cytology remain incorporated into screening. Here, 2 experts debate how to apply these guidelines to Ms. L, a 22-year-old woman who has never undergone cervical cancer screening.


Subject(s)
Teaching Rounds , Uterine Cervical Neoplasms , Adult , Early Detection of Cancer , Female , Humans , Mass Screening , United States , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/prevention & control , Vaginal Smears , Young Adult
5.
Ann Intern Med ; 175(8): 1161-1169, 2022 08.
Article in English | MEDLINE | ID: mdl-35939811

ABSTRACT

Pulmonary embolism can be acutely life-threatening and is associated with long-term consequences such as recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension. In 2020, the American Society of Hematology published updated guidelines on the management of patients with venous thromboembolism. Here, a hematologist and a cardiology and vascular medicine specialist discuss these guidelines in the context of the care of a patient with pulmonary embolism. They discuss advanced therapies such as catheter-directed thrombolysis in the short-term management of patients with intermediate-risk disease, recurrence risk stratification at presentation, and ideal antithrombotic regimens for patients whose pulmonary embolism was associated with a transient minor risk factor.


Subject(s)
Hypertension, Pulmonary , Pulmonary Embolism , Teaching Rounds , Venous Thromboembolism , Humans , Hypertension, Pulmonary/drug therapy , Pulmonary Embolism/complications , Pulmonary Embolism/drug therapy , Risk Factors , Venous Thromboembolism/complications , Venous Thromboembolism/drug therapy
6.
Ann Intern Med ; 174(4): 521-528, 2021 04.
Article in English | MEDLINE | ID: mdl-33844572

ABSTRACT

Aortic stenosis (AS) is common, especially among the elderly. Left untreated, severe symptomatic AS is typically fatal. Surgical aortic valve replacement (SAVR) was the standard of care until transcatheter aortic valve replacement (TAVR) was shown to have lower mortality rates in patients at the highest surgical risk and was recommended for this group in the 2014 American Heart Association/American College of Cardiology (AHA/ACC) guidelines. In the 2017 AHA/ACC focused update, evidence of benefit and noninferiority extended the use of TAVR to intermediate-risk patients. More recent studies suggest potential benefit to low-risk patients, although no published guidelines yet recommend the use of TAVR for this population. An advantage of SAVR is a 30-year experience with valve durability, but SAVR may have higher rates of perioperative death and a slower return of quality of life. Although TAVR has less than 10-year experience with valve durability, it has lower or noninferior primary end points, such as mortality and stroke, and fewer periprocedural complications among anatomically permissive patients. Here, a cardiologist and a cardiothoracic surgeon debate the risks and benefits of TAVR versus SAVR for a patient with severe symptomatic AS who is at low risk for surgical death.


Subject(s)
Aortic Valve Stenosis/surgery , Decision Making , Heart Valve Prosthesis Implantation , Transcatheter Aortic Valve Replacement , Aortic Valve Stenosis/diagnostic imaging , Echocardiography , Humans , Male , Middle Aged , Practice Guidelines as Topic
7.
Ann Intern Med ; 174(12): 1719-1726, 2021 12.
Article in English | MEDLINE | ID: mdl-34904883

ABSTRACT

Community-acquired pneumonia is a major cause of morbidity and mortality in the United States, leading to 1.5 million hospitalizations and at least 200 000 deaths annually. The 2019 American Thoracic Society/Infectious Diseases Society of America clinical practice guideline on diagnosis and treatment of adults with community-acquired pneumonia provides an evidence-based overview of this common illness. Here, 2 experts, a general internist who served as the co-primary author of the guidelines and a pulmonary and critical care physician, debate the management of a patient hospitalized with community-acquired pneumonia. They discuss disease severity stratification methods, whether to use adjunctive corticosteroids, and when to prescribe empirical treatment for multidrug-resistant organisms such as methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/drug therapy , Decision Making , Hospitalization , Pneumonia/drug therapy , Aged , Community-Acquired Infections/microbiology , Humans , Male , Massachusetts , Pneumonia/microbiology , Severity of Illness Index , Teaching Rounds
8.
Ann Intern Med ; 173(11): 914-921, 2020 12 01.
Article in English | MEDLINE | ID: mdl-33253616

ABSTRACT

Because pancreatic cancer is typically advanced at the time of diagnosis, it has a very low 5-year survival rate and may become the second leading cause of cancer death in the United States. A screening program to find early-stage pancreatic cancer is needed but has been challenging to develop because of the lack of an effective screening test. In 2019, the U.S. Preventive Services Task Force performed an evidence review and updated its guidance, confirming its 2004 "D" recommendation against routine screening for average-risk patients. Here, 2 experts review the updated guideline and recent evidence and discuss whether a patient with a family history of pancreatic cancer should undergo screening.


Subject(s)
Pancreatic Neoplasms/diagnosis , Early Detection of Cancer/adverse effects , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Risk Factors , Teaching Rounds
9.
Ann Intern Med ; 172(3): 202-209, 2020 02 04.
Article in English | MEDLINE | ID: mdl-32016334

ABSTRACT

The term transgender refers to persons whose gender identity is different from that recorded at birth. Similar to other marginalized populations, transgender patients commonly experience discrimination in the health care setting, and they may not have access to medical professionals who can provide competent care. In addition to primary medical and preventive health care, transgender patients need access to gender-affirming interventions, including hormone therapy and surgeries. In 2017, the Endocrine Society updated its clinical practice guideline for the care of transgender persons on the basis of the best available evidence from systematic reviews and individual studies. Among its general requirements for adolescents and recommendations for adults were the following: Involvement of a mental health professional who is knowledgeable about the diagnostic criteria for gender dysphoria and criteria for gender-affirming treatment, has training and experience in assessing psychopathology, and is willing to participate in ongoing care. Hormone therapy should be offered to transgender adult patients, with levels maintained within the normal range for gender identity and treatment appropriately monitored. Clinicians involved in the care of transgender adult patients should be knowledgeable about diagnostic criteria for gender dysphoria/gender incongruence, the use of medical and surgical gender-affirming interventions, and appropriate monitoring for reproductive organ cancer risk. Here, 2 clinicians with expertise in this area debate whether psychological evaluation is warranted in a transgender patient requesting gender-affirming hormones or surgery, the potential risks and benefits of estrogen therapy, and the role of the primary care practitioner in the care of transgender persons.


Subject(s)
Mental Health Services , Primary Health Care , Transgender Persons/psychology , Adult , Cardiovascular Diseases/chemically induced , Estrogens/adverse effects , Estrogens/therapeutic use , Female , Humans , Physician's Role , Practice Guidelines as Topic , Referral and Consultation , Risk Factors , Sex Reassignment Procedures , Thromboembolism/chemically induced
10.
J Gen Intern Med ; 35(3): 770-774, 2020 03.
Article in English | MEDLINE | ID: mdl-31808131

ABSTRACT

BACKGROUND: Medical scribes have been proposed as a solution to the problems of excessive documentation, work-life balance, and burnout facing general internists. However, their acceptability to patients and effects on provider experience have not been tested in a real-world model of effectiveness. OBJECTIVE: To measure the effect of medical scribes on patient satisfaction, provider satisfaction, and provider productivity. DESIGN: Quasi-experimental difference-in-differences longitudinal design. PARTICIPANTS: Four attending physicians who worked with scribes, 9 control physicians who did not, and their patients in a large, hospital-affiliated academic general internal medicine practice. MAIN MEASURES: Provider experience and patient experience using 5-point Likert scale surveys from the AMA Steps Forward Team Documentation Module, and visits and wRVUs per hour during 4 weeks before and 12 weeks after initiation of a practice model that included use of scribes and a shortened visit template. KEY RESULTS: Participating providers worked a total of 664 clinic sessions and returned 547 (82%) surveys. Average provider experience scores did not differ between providers working with scribes and control providers working without (4.01 vs. 3.40 respectively; p time-by-group interaction = 0.26). Providers with scribes were more likely to agree that work for the encounter would be completed during the visit then controls (3.58 vs. 2.48 respectively; p interaction = 0.04). A total of 6202 visits occurred during the study period. Average patient experience scores did not differ between the experimental and control groups (4.73 vs. 4.75 respectively; p interaction = 0.90). Compared with the control providers, providers with scribes completed more visits per hour (2.29 vs. 1.91; p interaction < 0.001) and generated more wRVUs per hour (3.42 vs. 3.27; p interaction < 0.001). CONCLUSIONS: In this test of a modified practice model, scribes supported greater patient throughput and improved provider perceptions of documentation burden with no decrement in high patient satisfaction.


Subject(s)
Documentation , Electronic Health Records , Patient Satisfaction , Health Personnel , Humans , Patient Outcome Assessment
11.
Ann Intern Med ; 170(7): 488-496, 2019 04 02.
Article in English | MEDLINE | ID: mdl-30934082

ABSTRACT

In 2016, the American Society of Clinical Oncology published a guideline recommending that all patients with advanced cancer be referred to palliative care providers. This recommendation was based on a series of trials showing that palliative care, when added to standard oncology treatment, improves outcomes, including quality of life. Here, 2 oncologists, 1 of whom is also a palliative care specialist, debate the guideline and discuss how best to care for a 71-year-old woman with metastatic neuroendocrine carcinoma who has a short life expectancy but feels well and has no symptoms related to her cancer or chemotherapy.


Subject(s)
Carcinoma, Neuroendocrine/therapy , Liver Neoplasms/therapy , Palliative Care , Referral and Consultation , Advance Care Planning , Aged , Antineoplastic Agents/therapeutic use , Carcinoma, Neuroendocrine/drug therapy , Carcinoma, Neuroendocrine/secondary , Female , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Oncologists , Patient Care Team , Physician's Role , Practice Guidelines as Topic , Teaching Rounds
12.
Ann Intern Med ; 171(3): 199-207, 2019 08 06.
Article in English | MEDLINE | ID: mdl-31382287

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD), a common diagnosis in the United States and other developed countries, has been increasing in prevalence. The American Association for the Study of Liver Diseases recently published updated practice guidelines for diagnosing and managing NAFLD, including the following recommendations: Routine screening for NAFLD in high-risk groups is not advised because of uncertainties surrounding test and treatment options, along with a lack of knowledge about cost-effectiveness and long-term benefits. Noninvasive studies, including biomarkers from laboratory tests and liver stiffness measured through elastography, are clinically useful tools for identifying advanced fibrosis in patients with NAFLD. Liver biopsy should be considered in patients with NAFLD who are at increased risk for nonalcoholic steatohepatitis (NASH) or advanced fibrosis. Weight loss of at least 3% to 5% generally reduces NASH, but greater weight loss (7% to 10%) is needed to improve most histopathologic features, including fibrosis. Pharmacologic therapies (such as pioglitazone and vitamin E) should be considered only in patients with biopsy-proven NASH. Patients with NAFLD should not consume heavy amounts of alcohol, although insufficient data exist to provide advice about other levels of alcohol use. Here, 2 clinicians with expertise in this area debate whether to screen for NAFLD in primary care, how to monitor patients with NAFLD, and what interventions should be used to manage this condition.


Subject(s)
Disease Management , Non-alcoholic Fatty Liver Disease/diagnosis , Non-alcoholic Fatty Liver Disease/therapy , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Biomarkers/blood , Biopsy , Elasticity Imaging Techniques , Humans , Liver/pathology , Male , Mass Screening , Middle Aged , Non-alcoholic Fatty Liver Disease/drug therapy , Practice Guidelines as Topic , Primary Health Care , Risk Factors , Weight Loss
13.
Ann Intern Med ; 168(3): 203-209, 2018 02 06.
Article in English | MEDLINE | ID: mdl-29404595

ABSTRACT

Hormone therapy (HT) was widely prescribed in the 1980s and 1990s and has been controversial since the initial results of the Women's Health Initiative (WHI) trial in the early 2000s suggested that it increased risk for breast cancer and coronary heart disease and did not prolong life. However, more recent data and reexamination of the WHI results suggest that HT is safe and effective for many women when used around the time of menopause. Two experts debate the 2017 Hormone Therapy Position Statement of The North American Menopause Society, which recommends HT as first-line treatment of vasomotor symptoms, and apply it to the care of Ms. R, a 52-year-old woman with severe hot flashes, sleep disturbance, and irritability.


Subject(s)
Antidepressive Agents, Second-Generation/therapeutic use , Estrogen Replacement Therapy/methods , Hot Flashes/drug therapy , Menopause , Sleep Wake Disorders/drug therapy , Venlafaxine Hydrochloride/therapeutic use , Female , Humans , Middle Aged , Quality of Life , Risk Assessment
14.
Ann Intern Med ; 168(7): 498-505, 2018 04 03.
Article in English | MEDLINE | ID: mdl-29610916

ABSTRACT

In 2015, the American Geriatrics Society released recommendations for prevention and management of postoperative delirium, based on a systematic literature review and evaluation of nonpharmacologic and pharmacologic approaches by an expert panel. The guidelines recommend an interdisciplinary focus on nonpharmacologic measures (reorientation, medication management, early mobility, nutrition, and gastointestinal motility) for prevention and consideration of this strategy for acute management. They also recommend optimizing nonopioid medication as a means to manage pain and avoiding benzodiazepines other than to treat substance withdrawal. The authors concluded that evidence to recommend antipsychotics for prevention of delirium is insufficient but that these drugs may be considered for short-term treatment in the setting of imminent harm to the patient or caregivers or severe distress due to agitation. Patients should be given the lowest possible dose for the shortest duration when other nonpharmacologic measures have failed. In this Beyond the Guidelines, a psychiatrist and a geriatrician debate whether Mr. W, a 79-year-old man at high risk for postoperative delirium, should receive prophylactic antipsychotics with his next surgery. They review risk factors, appropriate evaluation, and potential benefits and harms of the various medications often used in this setting.


Subject(s)
Antipsychotic Agents/therapeutic use , Delirium/prevention & control , Postoperative Complications/prevention & control , Aged , Humans , Male , Practice Guidelines as Topic , Risk Factors
15.
Ann Intern Med ; 167(11): 786-793, 2017 12 05.
Article in English | MEDLINE | ID: mdl-29204620

ABSTRACT

Aspirin exerts antiplatelet effects through irreversible inhibition of cyclooxygenase-1, whereas its anticancer effects may be due to inhibition of cyclooxygenase-2 and other pathways. In 2009, the U.S. Preventive Services Task Force endorsed aspirin for primary prevention of cardiovascular disease. However, aspirin's role in cancer prevention is still emerging, and no groups currently recommend its use for this purpose. To help physicians balance the benefits and harms of aspirin in primary disease prevention, the Task Force issued a guideline titled, "Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer" in 2016. In the evidence review conducted for the guideline, cardiovascular disease mortality and colorectal cancer mortality were significantly reduced among persons taking aspirin. However, there was no difference in nonfatal stroke, cardiovascular disease mortality, or all-cause mortality, nor in total cancer mortality, among those taking aspirin. Aspirin users were found to be at increased risk for major gastrointestinal bleeding. In this Beyond the Guidelines, the guideline is reviewed and 2 experts discuss how they would apply it to a 57-year-old man considering starting aspirin for primary prevention. Our experts review the data on which the guideline is based, discuss how they would balance the benefits and harms of aspirin therapy, and explain how they would incorporate shared decision making into clinical practice.


Subject(s)
Aspirin/therapeutic use , Cardiovascular Diseases/prevention & control , Platelet Aggregation Inhibitors/therapeutic use , Primary Prevention , Anticholesteremic Agents/therapeutic use , Aspirin/administration & dosage , Aspirin/adverse effects , Gastrointestinal Hemorrhage/chemically induced , Humans , Hypercholesterolemia/drug therapy , Male , Middle Aged , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/adverse effects , Pravastatin/therapeutic use , Risk Assessment
16.
Ann Intern Med ; 166(7): 506-513, 2017 04 04.
Article in English | MEDLINE | ID: mdl-28384742

ABSTRACT

The increase in overdose deaths from prescription opioids and heroin in the United States over the past 20 years is believed to have resulted from increases in prescription of opioids for management of acute and chronic pain. Managing chronic pain is challenging for primary care clinicians for many reasons, including the lack of evidence to guide practice. The Centers for Disease Control and Prevention published a comprehensive guideline in 2016 to help clinicians with opioid prescribing for chronic pain. In this Grand Rounds, the guideline is reviewed and an expert discusses its application to 3 patients prescribed opioids to treat chronic pain.


Subject(s)
Analgesics, Opioid/therapeutic use , Chronic Pain/drug therapy , Aged , Analgesics, Opioid/adverse effects , Chronic Pain/psychology , Communication , Female , Guideline Adherence , Humans , Male , Medication Adherence , Middle Aged , Physician-Patient Relations , Practice Guidelines as Topic , Practice Patterns, Physicians' , Prescription Drug Misuse/prevention & control
17.
Ann Intern Med ; 164(3): 176-83, 2016 02 02.
Article in English | MEDLINE | ID: mdl-26829911

ABSTRACT

Physicians and patients have come to expect that periodic health examinations (PHEs) are a standard part of comprehensive ongoing medical care. However, considerable research has not demonstrated a substantial benefit of the PHE. Given this lack of benefit and the high total cost of PHE to the health care system, the American Board of Internal Medicine (ABIM) Foundation and the Society of General Internal Medicine (SGIM) have identified "routine health checks in asymptomatic patients" as something of low value that physicians and patients should question, as a part of the Choosing Wisely campaign. Two discussants review the debate about PHE and consider the value of PHE for a healthy 70-year-old woman who appreciates seeing her physician annually.


Subject(s)
Guideline Adherence , Physical Examination , Practice Guidelines as Topic , Aged , Female , Health Care Costs , Humans , Physical Examination/economics , Primary Health Care/economics , Risk Assessment , Time Factors
18.
Ann Intern Med ; 165(11): 800-807, 2016 12 06.
Article in English | MEDLINE | ID: mdl-27919096

ABSTRACT

The U.S. Preventive Services Task Force (USPSTF) recently issued guidelines on screening for vitamin D deficiency. The guidelines were based on randomized trials of vitamin D deficiency screening and treatment, as well as on case-control studies nested within the Women's Health Initiative. The USPSTF concluded that current evidence is insufficient to assess the benefits and harms of screening for vitamin D deficiency in asymptomatic adults. Compared with placebo or no treatment, vitamin D was associated with decreased mortality; however, benefits were no longer seen after trials of institutionalized persons were excluded. Vitamin D treatment was associated with a possible decreased risk for at least 1 fall and the total number of falls per person but not for fractures. None of the studies examined the effects of vitamin D screening versus not screening on clinical outcomes. In this Grand Rounds, 2 prominent endocrinologists debate the issue of screening for vitamin D deficiency in a 55-year-old, asymptomatic, postmenopausal woman. They review the data on which the USPSTF recommendations are based and discuss the potential benefits and risks, as well as the challenges and controversies, of screening for vitamin D deficiency in primary care practice.


Subject(s)
Mass Screening , Practice Guidelines as Topic , Vitamin D Deficiency/diagnosis , Dietary Supplements , Female , Humans , Middle Aged , Postmenopause , Risk Assessment , Vitamin D/therapeutic use , Vitamin D Deficiency/complications , Vitamin D Deficiency/drug therapy
19.
Ann Intern Med ; 163(12): 941-8, 2015 12 15.
Article in English | MEDLINE | ID: mdl-26666782

ABSTRACT

The U.S. Public Health Service recently issued guidelines about the daily use of medication as preexposure prophylaxis (PrEP) to prevent HIV infection. The guidelines, based on randomized trials showing substantial reduction in HIV transmission among those receiving a daily combination of tenofovir and emtricitabine, suggest physicians offer PrEP to patients at high risk, including nonmonogamous men who have sex with men, serodiscordant couples (in both male-male and male-female relationships), heterosexual men and women in other risk groups (such as sex workers or those with recent sexually transmitted infection), and injection drug users. Here, 2 prominent HIV experts debate the use of PrEP in a 45-year-old man whose husband has HIV infection with an undetectable viral load on treatment. They discuss the patient's risk for HIV transmission from his husband and from other partners, the magnitude of the risk reduction he would gain with PrEP, and nonpharmacologic alternatives to reduce his likelihood of contracting HIV infection.


Subject(s)
HIV Infections/prevention & control , Pre-Exposure Prophylaxis , HIV Infections/transmission , HIV Infections/virology , Humans , Male , Middle Aged , Risk Assessment , Risk Factors , Sexual Partners , Viral Load
20.
Ann Intern Med ; 163(7): 537-47, 2015 10 06.
Article in English | MEDLINE | ID: mdl-26436618

ABSTRACT

Pelvic examinations have historically been a part of regular preventive care. However, because women can now be screened for cervical cancer at intervals up to every 5 years, the question of whether women need to be seen annually for routine pelvic examinations has arisen. In July 2014, the American College of Physicians (ACP) issued a guideline presenting the available evidence on screening for pathologic conditions using pelvic examination in adult, asymptomatic women at average risk. The American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice had previously issued a committee opinion in August 2012 on the need for annual examinations and provided guidelines on important elements of this procedure, including when to examine asymptomatic women. ACOG reaffirmed its initial position after publication of the ACP guideline. The guidelines differ-the ACP guideline recommends against and the ACOG committee opinion recommends in favor of routine annual pelvic examination. This paper summarizes a discussion between an internist and a gynecologist on how they would balance these recommendations in general and what they would suggest for an individual patient.


Subject(s)
Guideline Adherence , Gynecological Examination , Mass Screening , Practice Guidelines as Topic , Adult , Asymptomatic Diseases , Decision Making , Evidence-Based Medicine , Female , Humans , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/prevention & control , Physician's Role , Practice Patterns, Physicians' , Risk Factors , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL